FindTrial
Sign In

Checking of response to inhaled corticosteroid treatment on a new laboratory parameter (blood CD28) in patients of asthma

Evaluation of response to inhaled corticosteroid therapy on serum CD28 levels in adult bronchial asthma patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2015/07/005977
Enrollment
80
Registered
2015-07-07
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J454- Moderate persistent asthma

Interventions

None listed

Sponsors

Lady Hardinge Medical College
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed patients of bronchial asthma of mild to moderate severity who will be started on inhaled corticosteroids according to standard treatment of care.

Exclusion criteria

Exclusion criteria: Pregnancy Smoking Acute severe asthma patients who have taken corticosteroids in any form in last 4 weeks patients with any other co-existent and active pulmonary infection

Design outcomes

Primary

MeasureTime frame
Comparison of serum CD28 levels in asthmatic patients with healthy adults Change in serum levels of CD28 in asthmatic patients after treatment with inhaled corticosteroidsTimepoint: 4 weeks—

Secondary

MeasureTime frame
Correlation between asthma severity score as measured by SOA questionnaire and CD28 level Change in quality of life scores in asthma as measured by QOLtech AQLQ questionnaire, after treatment with inhaled corticosteroidsTimepoint: 4weeks—

Countries

India

Contacts

Public ContactDr Anubhuti Gupta

Lady Hardinge Medical College

lkg71@rediffmail.com9868234013

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026